CLPT · ClearPoint Neuro, Inc.

ClearPoint Neuro delivered a strong first quarter in 2026, with total revenue reaching $12.1 million, a 43% increase year-over-year. The growth was driven by a 25% organic increase in devices revenue and the contribution from the IRRA flow acquisition, which closed in November 2025. Neurosurgery navigation, therapy and access revenue surged 80% to $5.9 million, benefiting from IRRA flow sales and the new 3.0 operating room navigation software. Capital equipment and software revenue more than doubled to $1.4 million, reflecting increased placements of navigation systems, IRRA flow control units, and Prism laser units. Biologics and drug delivery revenue was relatively flat at $4.8 million, as the company continues to expand its ClearPoint Advanced Laboratories (CAL) facility to boost future capacity. Gross margin improved to 64% from 60% in the prior year, primarily due to lower excess and obsolete inventory charges. Operating expenses rose 44% to $16.2 million, driven by higher personnel costs from the IRRA flow integration and increased occupancy and travel expenses. The company ended the quarter with $35.6 million in cash, down from $45.9 million at year-end 2025, reflecting $8.0 million used in operations and $2.0 million for tax-related share settlements. Management reiterated its full-year 2026 revenue guidance of $52 million to $56 million, expecting double-digit growth across all four strategic pillars. The integration of IRRA flow is on track, with cost synergies anticipated to reduce cash burn in the second half of 2026 and potentially achieve cash neutrality for the full year 2027. Notable operational achievements include FDA clearance and first clinical use of the Velocity Alpha MR High Speed Surgical Drill System, receipt of a Medical Device License from Health Canada for the ClearPoint Neuro Navigation System, and completion of the first commercial drug delivery case in the Asia-Pacific region. The company's installed base now exceeds 175 global centers, and it continues to support over 60 active biopharma partners.